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Several chemical substances belonging to classes of natural dietary origin display pro-
tective properties against some age-related diseases including neurodegenerative ones,
particularly Alzheimer’s disease (AD). These compounds, known as nutraceuticals, differ
structurally, act therefore at different biochemical and metabolic levels and have shown
different types of neuroprotective properties. The aim of this review is to summarize data
from observational studies, clinical trials, and randomized clinical trials (RCTs) in humans
on the effects of selected nutraceuticals against age-related cognitive impairment and
dementia. We report results from studies on ﬂavonoids, some vitamins and other natural
substances that have been studied in AD and that might be beneﬁcial for the maintenance
of a good cognitive performance. Due to the substantial lack of high-level evidence studies
there is no possibility for recommendation of nutraceuticals in dementia-related therapeutic
guidelines. Nevertheless, the strong potential for their neuroprotective action warrants
further studies in the ﬁeld.
Keywords: cognitive impairment, dementia, Alzheimer’s disease, dietary natural substances, neurodegeneration,
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INTRODUCTION
Advanced age is often characterized by adecline in a large spectrum
of cognitive abilities including reasoning, memory, perceptual
speed, and language. The impairment of more of these activi-
ties, when lasting long enough and being associated to functional
loss is referred to as dementia. Alzheimer’s disease (AD) is the
most common and feared form of dementia representing circa
70% of all dementia cases and displaying a dramatic epidemics
due to the enormous growth of the aged population worldwide.
Incidence of dementia has increased over the recent years although
recent epidemiological studies seem to show a decline that needs
to be conﬁrmed in the future (Larson et al., 2013). The num-
ber of cases is expected to approach a million people per year in
USA by 2050 (Alzheimer’s Association, 2009). AD impacts dra-
matically on everyday life of older adults, being one of the main
causes of disability in the old age. There has been an increas-
ing interest in the past decades about interventions that may
help to improve cognitive performance in older age or, at least,
delay the onset of dementia. Due to the absence of a cure against
dementia and AD, the public health priority has focused more
recently on prevention of cognitive decline. It is still unclear which
factors lead to the molecular cascade of neurodegeneration in
AD, but along with genetic and environmental factors vascular
pathology and risk factors have been recently shown to play a
crucial role in AD pathogenesis (Polidori et al., 2012). Therefore,
lifestyle strategies with beneﬁcial effects on neurodegeneration
and vascularity – including natural nutrition and nutritional sup-
plementation, cognitive and social activity, physical exercise –
have been identiﬁed as possible target options for AD prevention
(Brown et al., 2010; Polidori et al., 2012; Polidori and Schulz,
2014).
The effect of a correct diet on human health has been reported
in many epidemiological studies and randomized controlled tri-
als (RCTs; Everitt et al., 2006). There is clear evidence that a
diet rich in speciﬁc nutritional food groups (fruit, ﬁsh, vegeta-
bles) can reduce the incidence and prevalence of some of the
main clinical outcomes, such as neurodegenerative disorders, car-
diovascular diseases, diabetes, cancer (Grant, 1999; Panza et al.,
2004; Soﬁ et al., 2008; Frisardi et al., 2010). These speciﬁc nutri-
tional food groups are rich in micronutrients and vitamins that,
for their characteristic of being of nutritional nature and ben-
eﬁcial for health (like pharmaceuticals) at the same time, have
been deﬁned as nutraceuticals by De Felice in 1989 (Kalra, 2003).
Among different types of diet, theMediterranean pattern obtained
a considerable amount of interest in the past recent decades due
to the results of large epidemiological and bench studies show-
ing its high content in nutraceuticals. The Mediterranean diet
is characterized by a high consumption of plant foods, ﬁsh,
olive oil as primary sources of monounsaturated fat and mod-
erate intake of wine. This kind of food intake pattern might
be particularly healthy due to synergistic actions of its com-
ponents. Synergistic mechanisms between food components are
responsible particularly for the neuroprotective effects displayed
by certain nutrients and nutraceuticals. In addition, cardiovas-
cular diseases such as diabetes mellitus, hypertension, and lipid
disorders, as well as white substance lesions are highly susceptible
to micronutrient changes. This might be particularly important
in light of the recently shown major pathophysiological role of
vascular pathology and risk factors in both AD and its prodro-
mal phase, mild cognitive impairment (MCI; De la Torre, 2010;
Polidori et al., 2012; Féart et al., 2013). Independent of the mech-
anism through which the Mediterranean dietary pattern exerts its
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beneﬁcial effects, a large amount of studies have recently shown its
protective activity against MCI and AD (systematically reviewed
and meta-analyzed by Singh et al., 2013 and Psaltopoulou et al.,
2013).
The aim of this review was to present evidence on a particular
group of plant and food components, the so-called nutraceuticals,
which have displayed over the years the ability or a strong potential
to act as neuroprotectans and/or delay cognitive impairment.
Practically, no ofﬁcial deﬁnition exists for the term “nutraceu-
tical,” though it is often used to describe a broad list of products
sold under the premise of food components with an expressed
intent of treatment or prevention of disease and for enhancing the
health and wellbeing of an individual (Hardy et al., 2003). In other
words, nutraceuticals are foods, or food components, that provide
medical or health beneﬁts, including prevention and treatment of
several diseases (Calabrese et al., 2009).
In this review, we focused our attention on a group of sub-
stances proposed to prevent or treat cognitive impairment or
dementia, with a particular attention on AD. Nutraceuticals
evaluated in humans in epidemiological, observational, or clin-
ical studies as well as in RCTs were selected. Only molecules
with stronger evidence for neuroprotection as well as those
more widely studied were included. To avoid redundancies,
we refer the reader to our previous studies for the role and
use of vitamin E family (Mangialasche et al., 2010, 2012, 2013;
Mecocci and Polidori, 2012; Mecocci et al., 2013) and to recent
reviews for the role and use of vitamin C (Heo et al., 2013;
Harrison et al., 2014) and of omega-3 fatty acids (Lin et al.,
2012; Sydenham et al., 2012; Dacks et al., 2013; Denis et al.,
2013).
FLAVONOIDS
Flavonoids are a group of poliphenolic compounds that are very
common in the daily human diet. They are found in most plants,
including fruits, vegetables, and several types of natural drinks
such as tea, cocoa and wine (Manach et al., 2004; Spencer et al.,
2008).
On the basis of their chemical structure they can be divided
into six subgroups (Table 1).
Flavonoids and their metabolites modulate several neurolog-
ical processes as shown by studies in which an interaction with
neuronal-glial signaling pathways involved in neuronal survival
and function was observed (Spencer, 2010; Williams and Spencer,
2012). In addition, ﬂavonoids induce changes in cerebral blood
ﬂow (Francis et al., 2006; Fisher et al., 2006; Williams and Spencer,
2012), upregulate antioxidant enzymes and proteins involved in
synaptic plasticity and neuronal repair (Mann et al., 2007; Eggler
et al., 2008; Spencer, 2009) and inhibit neuropathological pro-
cesses in brain regions typically involved in AD pathogenesis
(Wang et al., 2008a).
FLAVANOLS: CATECHIN, EPICATECHIN, EPIGALLOCATECHIN,
EPIGALLOCATHECHIN GALLATE
Flavanols are a main ﬂavonoid group and are found in cocoa and
chocolate as well as in black and green tea and in grapes. Research
over the past decade has identiﬁed ﬂavanols as showing diverse
beneﬁcial physiologic and antioxidant effects, particularly in the
context of vascular function (Francis et al., 2006).
Catechin and epicatechin are the most abundant ﬂavanols in
grape seeds and grape juice. A study on supplementation of grape
juice from a variety of Vitis vinifera called Koshu demonstrated
an inhibition of glutamate excitotoxicity (Narita et al., 2011). In
humans, few clinical trials with grape juice have shown that short-
and moderate-term supplementation produces beneﬁt in indi-
viduals with cerebrovascular diseases including increased serum
antioxidant capacity and reduced LDL oxidation, improvement
of endothelial function and reduction of platelet aggregation
(Krikorian et al., 2010a).
Daily EGCG treatment in rats has been demonstrated to reduce
the progressive increase of oxidative stress induced by hyperten-
sion. EGCG also decreases the concentration of reactive oxygen
species on hippocampus. Based on these results a therapeutic
effect of EGCG in treating vascular-induced learning and mem-
ory impairment has been proposed (Wang et al., 2012). Black and
green teas have a high content of catechins, being EGCG the most
abundant. There are several studies that show the protective effect
of catechins in cellular and animal models of AD. Despite the lack
of clinical trials with tea polyphenols in neurodegenerative dis-
eases, epidemiological observations inUS andFinnish populations
showed a reduced risk of Parkinson’s disease in high consumers of
tea (Checkoway et al., 2002; Hu et al., 2007) and a reduced risk of
cognitive impairment in a Japanese population drinking green tea
(Kuriyama et al., 2006).
Consumption of cocoa ﬂavanols has been previously shown to
inﬂuence cerebral hemodynamics. It has been suggested that one
consequence of the effect of cocoa ﬂavanols on cerebral blood ﬂow
Table 1 | Flavonoid chemical subgroups and relative food sources.
Groups Molecules Food source
FLAVANOLS Catechin, epicatechin, epigallocathechin, epigallocatechin gallate (EGCG) Cocoa and chocolate, green tea, grapes
FLAVONOLS Kaempferol, quercetin Onions, apples, green tea, capers, leeks, broccoli
FLAVONES Luteolin, apigenin Celery, parsley, rosemary
ISOFLAVONES Daidzein, genistein Soy
FLAVANONES Hesperetin, naringenin Citrus fruit, tomatoes
ANTHOCYANIDINS Pelargonidin, cyanidine, malvidin Berry fruits, red wine
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might be to improve performance on visual and cognitive tasks as
shown after drinking of cocoa beverages (Scholey et al., 2010; Field
et al., 2011).
FLAVONOLS: QUERCETIN, KAEMPFEROL
Quercetin, one of the most studied bioﬂavonoids, is found in
many common foods, such as capers, apples, onions and green tea
(Kelsey et al., 2010). Its primary activity is to prevent endothelial
apoptosis caused by oxidants, thanks to a highly potent antioxi-
dant activity and cytoprotective effects (Dong et al., 2012). There
are several in vitro studies about quercetin effects demonstrating
that this molecule increases cell survival in neurotoxic conditions
as in the presence of hydrogen peroxide (Heo and Lee, 2004),
linoleic acid hydroperoxide (Sasaki et al., 2003; Kelsey et al., 2010),
interleukin-1β (Sharma et al., 2007; Kelsey et al., 2010). In vivo
studies have demonstrated that quercetin could have a role in vas-
cular dementia by decreasing the size of ischemic lesions (Dajas
et al., 2003; Kelsey et al., 2010). Quercetin improves memory and
hippocampal synaptic plasticity in models of impairment induced
by chronic lead exposure and it could have a role in neuronal
repairing, as shown in spinal cord injury models (Schültke et al.,
2003).
Kaempferol is widely distributed in the humandaily diet such as
fruits, beverages, tea, and vegetables (Aherne and O’Brien, 2002).
Kaempferol protects PC12 cells against the oxidative stress induced
by H2O2 (Hong et al., 2009) and improves cognitive learning
and memory capability in mice (Lei et al., 2012). It was reported
that the intake of ﬂavonols including quercetin, kaempferol, and
myricetin has favorable effects on cognitive performance (Spencer,
2009).
Ginkgo biloba (Gb) is a plant whose herbal extracts (mainly
EGb761) are often used as an alternative treatment to improve
cognitive function. Extracts of Gb include several components,
such as the ﬂavonols quercetin and kaempferol as well as terpenoid
lactones that are considered to be responsible for the neuroprotec-
tive functions of Gb (Rendeiro et al., 2012). Standardized extracts
of Gb leaves are studied for their potential to improve memory
and cognitive function in general. Hemodynamic, neurotransmit-
ter, and free-radical scavenging effects of Gb have been shown in
several studies. All of these biological functions may be relevant
to aging and age-related disorders (Maclennan et al., 2002; Brown
et al., 2010). For this reason, several in vivo studies from humans
have been performed and beneﬁcial effects of Gb in prevention
and treatment of neurodegenerative disorders like AD have been
shown. Improvement of cognitive performance (Le Bars et al.,
1997; Kanowski and Hoerr, 2003),memory (Kanowski and Hoerr,
2003), and attention (Le Bars, 2003; Chan et al., 2007) were con-
sistently observed. Two large RCTs on the use of Gb extracts (the
GEM and the GuidAge study) did not show less cognitive decline
over time in older adults with normal cognition or MCI taking Gb
than those assuming placebo (Snitz et al., 2009; Vellas et al., 2012).
Also, Gb showed no effects in reducing either the overall incidence
rate of dementia or AD in old age individuals with normal cogni-
tion orMCI (DeKosky et al., 2008). The latest publishedCochrane
review including 36 RCTs could not report a signiﬁcant evidence
for a predictable clinical beneﬁt of Gb for people with dementia
or cognitive impairment (Birks and Grimley Evans, 2009).
FLAVONES: LUTEOLIN, APIGENIN
Luteolin is the most abundant ﬂavonoid in plants such as rose-
mary, celery, and parsley (Chowdhury et al., 2002; El Omri et al.,
2012). It has been shown that luteolin has several pharmacologi-
cal properties including a protective role of DNA against hydrogen
peroxide-induced toxicity and anti-inﬂammatory actions (Cheng
et al., 2010; El Omri et al., 2012).
Apigenin was shown to protect neurons against Aβ-mediated
toxicity induced by copper, to increase neuronal viability as well
as to relieve mitochondrial membrane dissipation and neuronal
nuclear condensation (Zhao et al., 2013). Apigenin also modulates
GABAergic and glutamatergic transmission in cultured cortical
neurons (Losi et al., 2004). Up to now no clinical studies have been
performed with luteolin and apigenin in cognitive impairment
or AD.
ISOFLAVONES: SOY - GENISTEIN, DAIDZEIN, GLYCITIN
Soybean (soy) is a rich source of phytoestrogens, especially
isoﬂavones. These are not the only constituents of soy; in fact,
soybean contains also several minerals, ﬁbers, proteins and
oligosaccharides. The isoﬂavones from soybean are considered
agonists of estrogen receptors. The presence of soy isoﬂavones
may be responsible for the observed memory-improving effects
of soybean supplementation. Isoﬂavones appear to improve cog-
nitive function by mimicking the effects of estrogen, in particular
through estrogen receptor β in the brain (Lee et al., 2004a). Estro-
gen replacement can improve cholinergic function by increasing
choline uptake and potassium-stimulated acetylcholine release
(Gabor et al., 2003; Bansal and Parle, 2010). Former studies
revealed that soy isoﬂavones improve visual spatial memory and
learning ability as well as memory of male and female animals
(Duncan et al., 2003; Lee et al., 2004b) and humans (File et al.,
2001; Zhao and Brinton, 2007; Bansal and Parle, 2010). Fur-
thermore, soy isoﬂavones can inﬂuence the brain cholinergic
system and reduce age-related neuronal loss and cognition decline
in male rats (Lee et al., 2004b). A study on young and mature
mice (Bansal and Parle, 2010) demonstrated that chronic dietary
supplementation with soybean improves cognitive performance,
decreases thiobarbituric acid reactive substances (TBARs) and
increases plasma glutathione peroxidase levels, suggesting that soy
isoﬂavones have antioxidant properties (Djuric et al., 2001; Lee
et al., 2004b).
Few RCTs have been performed with soy supplementation,
with controversial results. A long-term supplementation of soy
in women had no effect on global cognition but improved visual
memory after thirty months (Henderson et al., 2012), while in
men, treated for twelve weeks, only spatial working memory
improved compared to the placebo group (Thorp et al., 2009). A
previous study in postmenopausal women who received soy pro-
tein for twelve months had no beneﬁt in cognitive performance
(Kreijkamp-Kaspers et al., 2004).
ANTHOCYANIDINS: PELARGONIDIN, CYANIDINE, MALVIDIN
Blueberry, bilberry, cranberry, elderberry, raspberry seeds,
and strawberry are sources of natural anthocyanin antiox-
idants. Proanthocyanidins extracted from grape seeds (the
bark of the Chinese Scutellaria baicalensis herb) exert potent
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anti-inﬂammatory, antioxidant, antinociceptive, and vasodi-
latative effects and may show antidepressant properties (Ogle
et al., 2013). Berry anthocyanins also improve neuronal and
cognitive brain function, ocular health as well as pro-
tect genomic DNA integrity (Zafra-Stone et al., 2007). How-
ever, blueberries also contain signiﬁcant amounts of ﬂa-
vanols, ﬂavonols, and other phenolics which may justify
their role in increasing their beneﬁcial effects (Harnly et al.,
2006).
After blueberries feeding, anthocyanidins are found in speciﬁc
cerebral sites, including hippocampus and neocortex (Andres-
Lacueva et al., 2005). Neurogenesis acting on hippocampus may
represent one mechanism by which blueberry ﬂavonoids improve
memory. There is strong evidence suggesting that blueberry can
improve memory and learning in aged animals. These improve-
ments seem linked to the modulation of important structural and
synaptic plasticity markers (Rendeiro et al., 2012). One of the role
of anthocyanins in neuroprotection could be mediated through
phospholipase A2 inhibition (Frisardi et al., 2010), which is nega-
tively involved in a complex network of signaling pathways linking
receptor agonists, oxidants, and proinﬂammatory cytokines to the
release of arachidonic acid and eicosanoid synthesis (Sun et al.,
2004).
Memory performance has been demonstrated to be linked
to the modulation of the expression of particular proteins like
CREB (cAMP-response element-binding protein), which is a path-
way known to be activated in response to Aβ and brain-derived
neurotrophic factor (BDNF). Changes in CREB and BDNF in
berry-feed animals were accompanied by increases in the phos-
phorylation state of the protein factor ERK, very important for
synaptic plasticity and memory formation (Williams et al., 2008).
Furthermore, blueberry seems to have a more signiﬁcant effect
on short-term memory than long-term memory, as demon-
strated by improved performance in several memory maze tasks
(Ramirez et al., 2005; Williams et al., 2008; Rendeiro et al., 2012).
Another study (Fuentealba et al., 2011) that underlines the role of
berries-extract against Aβ shows how these extracts could partially
antagonize two newly found effects of Aβ: the decrease in intracel-
lular Ca2+ activity, an important element in neurodegenerative
processes and ATP leakage, an effect of aggregated Aβ (Petrozzi
et al., 2007). Short-time blueberry diet might produce beneﬁts on
memory in aged rats (Malin et al., 2011) by a suggested alteration
of ROS signaling through CREB and MAP-kinase (Brewer et al.,
2010). Inﬂammation pathways and modulation of the expres-
sion of inﬂammatory genes might also be involved (Shukitt-Hale
et al., 2008). Finally, there is evidence that anthocyanins have
insulin-like and glitazone-like properties which may contribute
to improve metabolic function and lipid lowering effects (Kalt
et al., 2008; Tsuda, 2008; Krikorian et al., 2010b) as well as to
improve memory and reduce depressive symptoms (Krikorian
et al., 2010b).
In humans, a prospective evaluation with a food frequency
questionnaire showed that a greater intake of blueberries and
strawberries is associated with slower rates of cognitive decline in
subjects older than seventy years, suggesting the potential protec-
tive role of berries on different cognitive functions (Devore et al.,
2012).
NON-FLAVONOID POLYPHENOLS: RESVERATROL AND
CURCUMIN
There is evidence that both resveratrol and curcumin, non-
ﬂavonoid polyphenols, show beneﬁcial effects in cell culture and
in vivo models of neurotoxicity and neurodegeneration.
Resveratrol is a polyphenol found enriched in seeds
and skin of several fruits, including grapes used for red
wine. It is well known mostly for its cardiovascular effects
(Bertelli and Das, 2009; Kelsey et al., 2010). Recent evi-
dence has shown that resveratrol can increase 5-HT activity,
which could explain its antidepressant properties (Ogle et al.,
2013). In animal models it has been shown that resvera-
trol inhibits noradrenalin and 5-HT reuptake in rats, with
increasing hippocampal serotonin (Xu et al., 2010). Resvera-
trol is also able to reduce inﬂammation and protect neu-
rons from death, as shown by in vivo experiments on ani-
mal models of oxidation-induced neuronal toxicity (Alvira
et al., 2007; Kelsey et al., 2010). Protection of organotypic
hippocampal slices from hydroperoxide insults has been also
observed (Karlsson et al., 2000; Kelsey et al., 2010). Other
possible mechanisms for the neuroprotective action dis-
played by resveratrol are related to its antioxidant properties
and its capacity of modulation of Aβ processing and up-
regulation of the longevity-linked gene sirtuin 1 (Pocernich et al.,
2011).
Several studies in humans have shown a lower risk of dementia
in subjects drinking moderate amounts of red wine when com-
pared to abstainers (Orgogozo et al., 1997; Truelsen et al., 2002).
Furthermore, a small clinical trial in healthy adults showed an
increase of cerebral blood ﬂow during cognitive tasks in sub-
jects treated with resveratrol compared to placebo (Kennedy et al.,
2010).
Curcumin is the most active element of tumeric (Curcuma
longa), an herb of the ginger family. It has been a staple of
oriental medicine for thousands of years (Ogle et al., 2013).
Since the prevalence of AD in Indian countries is much lower
than in US, it has been suggested that a diet rich in curcumin
may reduce the risk of AD (Ganguli et al., 2000). Curcumin
seems to act with different mechanisms including antioxidant,
anti-inﬂammatory and anti-amylodogenic ones. For example,
curcumin enhances cell viability by decreasing ROS and inhibit-
ing pro-apoptotic signals in mouse models of encephalitis (Dutta
et al., 2009; Kelsey et al., 2010). It also reduces Aβ-related cere-
bral burden and inﬂammation in transgenic AD mice (Lim et al.,
2001). It has been proposed that curcumin exerts most of its
effects by inhibiting monoamine oxidase levels, thereby reducing
depression also because it modulates serotonergic, dopaminer-
gic, and noradrenergic transmission (Xu et al., 2012; Ogle et al.,
2013).
A 6-month RCT performed in patients with AD showed no
beneﬁcial results in cognitive performances (Baum et al., 2008).
More recently, a randomized clinical trial with Curcumin C3
Complex -consisting of 95% curcuminoids with 70–80% com-
prised by curcumin, 15–25% demethoxycurcumin, and 2.5–6.5%
bisdemethoxycurcumin-was conducted in mild to moderate AD
with no evident beneﬁt on cognitive functions (Ringman et al.,
2012).
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CAROTENOIDS
Over 700 different members of the carotenoid family have been
identiﬁed and about 40 are found in human blood and tis-
sue. Major carotenoids in human organism are lycopene, lutein,
zeaxanthin, β-cryptoxanthin, α-carotene, and the most promi-
nent carotenoid, β-carotene. Depending on dietary habits, blood
levels vary between 0.01 and 1 mol/L but they can be consid-
erably increased upon supplementation with single compounds
or mixtures (Stahl et al., 1992). For structural reasons and
based on experimental data carotenoids have been assigned as
antioxidants (Krinsky and Johnson, 2005). Carotenoids as nat-
ural fat-soluble pigments are found mostly in vegetables and
fruits that are red, orange, and deep yellow in color. More
recently, astaxanthin, a carotenoid mainly present in seafood,
has been extensively studied in in vitro and in vivo models,
showing antioxidant and anti-inﬂammatory properties as well
as protective functions in microcirculation and in mitochondrial
functions (Kidd, 2011) suggesting a potential efﬁcacy in sev-
eral neurodegenerative diseases (Barros et al., 2014). High plasma
carotene concentrations associated with lower mortality from all
causes were shown by the SENECA investigators (Buijsse et al.,
2005), although conﬂicting data from intervention studies with
β-carotene to prevent cancers and cardiovascular disorders have
challenged the concept (Polidori and Stahl, 2009). Like other
important carotenoids of the antioxidant network, lutein and
zeaxanthin, the predominant carotenoids of the macula lutea,
are suggested to act as photoprotectants preventing age-related
degeneration of the macula lutea (Sabour-Pickett et al., 2012).
Astaxanthin showed a protective effect for visual problems, such as
blurred vision or reduced visual acuity, and also improved muscle
strength and endurance in runners and in soccer players (Kidd,
2011).
Patients with moderate to severe AD showed lower plasma lev-
els of two major carotenoids, lutein, and β-carotene, compared to
patients with mild AD or controls (Wang et al., 2008b). Among
AD patients a lower MMSE score (Mini Mental State Examina-
tion, a measure of cognitive performance) was associated with
lower lutein andβ-carotene levels in this study (Wang et al., 2008b).
Lycopene displays not only sun protective effects (Stahl et al., 2006)
but also beneﬁcial effects against development of prostate cancer
(Seren et al., 2008). Among six carotenoids tested, lycopene was
the only carotenoid inversely associated with quality of cogni-
tive performance as assessed by both MMSE, DemTect (Dementia
Detection Test) and Clock Drawing Test in healthy subjects from
45 to 102 years of age (Polidori et al., 2009).
A randomized trial with beta carotene supplementation in men
participating to the Physicians’Health Study showed, after a mean
treatment duration of 18 years, better cognitive performances in
the treated compared to the placebo group. The same effect was
not observed in newly randomized subjects after one year treat-
ment, suggesting that efﬁcacy of beta carotene can be obtained
only after a long term supplementation (Grodstein et al., 2007). In
a multicenter trial in old age subjects suffering from MCI, a dietary
supplement of astaxanthin, phosphatidylserine, and vitamin E
improved memory skills after sixty days of treatment, suggesting
a signiﬁcant potential role of his kind of supplementation in
counteracting age-related cognitive decline (Zanotta et al., 2014).
CROCIN – SAFFRON
Crocin is the main chemical compound identiﬁed in saffron,
whose scientiﬁc name is Crocus sativus. It has been used over the
years in folkmedicine as an antispasmodic, gingival sedative, nerve
sedative, carminative, and expectorant stimulant (Akhondzadeh
and Abbasi, 2006; Akhondzadeh et al., 2010). It has been reported
that saffron active constituents have anticonvulsant, antidepres-
sant, and anti-inﬂammatory effects, and improve learning and
memory (Schmidt et al., 2007). Crocin is the actual active compo-
nent involved in both the improvement of learning and memory
and preventing effect of long termpotentiation blocked by ethanol
(Akhondzadeh andAbbasi, 2006) and its potential in the treatment
of neurodegenerative diseases likeAD (Khalili andHamzeh, 2010).
In animal models, the effectiveness of crocin has been shown in
antagonizing the cognitive deﬁcits caused by neurotoxic agents like
streptozocin (Naghizadeh et al., 2013).
Crocin improved cognition as evaluated by means of ADAS-
Cog and CDR-SB in subjects with mild to moderate AD
(Akhondzadeh et al., 2010). In a recent in vivo study, it has
been demonstrated that crocin signiﬁcantly modulate the levels
of oxidative markers in the hippocampus, abolishing the deleteri-
ous effects of chronic stress on learning and memory (Ghadrdoost
et al., 2011).
B-VITAMINS: FOLATE, COBALAMIN, PYRIDOXIN
Folate (vitamin B9), cobalamin (vitamin B12), and pyridoxin
(vitamin B6) are the most studied B-vitamins in the ﬁeld of cogni-
tive decline and dementia (Brown et al., 2010). They are essential
for maintaining the integrity of the nervous and hematopoietic
systems (Malouf and Areosa Sastre, 2009).
Folate is absorbed from the diet and its decrease in blood is
highly dependent on a poor diet, malabsorption, and alcoholism;
cobalamin deﬁciency is also associated with malabsorption due
to digestive disorders occurring in older adults, and can result in
irreversible neurological disorders such as peripheral neuropathy
(Rébeillé et al., 2007; Clarke, 2008). Vitamin B6 - comprising three
chemically distinct compounds, pyridoxal, pyridoxamine, and
pyridoxine - is involved in the regulation of mental function and
mood. It is also an essential homocysteine re-methylation cofactor,
and its deﬁciency is associated with an increase in blood homo-
cysteine levels (Malouf and Grimley Evans, 2003). Poor vitamin
B6 status is common among older people. Folate and cobal-
amine deﬁciencies cause accumulation of homocysteine. Many
studies have found cross-sectional associations between low cir-
culating folate levels or hyperhomocysteinemia and low MMSE
scores (Morris and Jacques, 2009; Morris et al., 2012). Vitamin
B12 is involved in the methylation of homocysteine to methio-
nine for the synthesis of methyl acceptors such as membrane
phospholipids, myelin and neurotransmitters. Homocysteine is
potentially toxic to neurons, its levels have been associated
with atrophic changes in the brain and are negatively corre-
lated with neuropsychological tests scores; it is also considered
a marker for low serum vitamin B12 and folate (Ellinson et al.,
2004).
Aprospective study over a 4, 5-year period found that homocys-
teine is a risk factor for dementia or cognitive impairment (Haan
et al., 2007). In this study, plasma cobalamin levels were associated
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with reduced risk (Haan et al., 2007). A recent clinical cohort trial
found that plasma homocysteine levels are inversely related to
cognitive performance, but no evidence of a signiﬁcant protec-
tion of high plasma folate against dementia was found (Morris
et al., 2012). However, B12- and B6-vitamin treatment has been
demonstrated to stabilize performance on the CLOX test (Royall
et al., 1998) as well as on executive and planning function (De
Jager et al., 2012). Kado et al. (2005) and colleagues demonstrated
that folate, but not cobalamin levels, are independently predictive
of cognitive decline over a 7-year period in high functioning old
people.
These heterogeneous and contradictory results are reported
in the last Cochrane reviews, in which a signiﬁcant effect of
B-vitamin treatment in cognitive function could overall not be
reported (Malouf and Grimley Evans, 2008; Malouf and Areosa
Sastre, 2009).
Supplementation with B vitamins including vitamin B6 has
been shown to reduce blood homocysteine levels. In addition,
B6 vitamin concentration has been associated with better global
cognition scores, especially with better attention, and executive
function scores (Moorthy et al., 2012). Although vitamin B6 did
not succeed in reducing atherosclerotic manifestations in hyper-
homocysteinemic patients (Cacciapuoti, 2013), neuropsychiatric
disorders - seizures, migraine, chronic pain, and depression -
have been linked to vitamin B6 deﬁciency. However, there is
no evidence that short-term treatment with vitamin B6 improves
mood (depression, fatigue, and tension symptoms) or cognition
(Malouf and Grimley Evans, 2003).
Recent RCTs on the effects of folate, vitamin B12, and vitamin
B6 supplementation have been performed in subjects with mild
to moderate AD. These failed in showing any effect of supplemen-
tation in slowing cognitive decline (Sun et al., 2007; Aisen et al.,
2008; Malouf and Grimley Evans, 2008; Malouf and Areosa Sastre,
2009). A review on supplementation of vitamins B12, B6, and folic
acid alone or in combination showed that results from nineteen
RCTs did not appear to improve cognitive function in individuals
with or without existing cognitive impairment (Ford andAlmeida,
2012). So, it remains to be established if prolonged treatment with
B-vitamins can reduce the risk of dementia in later life. However,
in a recent study high-dose B-vitamin treatment (folic acid, vita-
min B6, and vitamin B12) not only slowed shrinkage of the whole
brain volume over 2 years but it reduced, by as much as seven-
fold, the cerebral atrophy in those gray matter regions speciﬁcally
vulnerable to the AD process, including the medial temporal lobe
(Douaud et al., 2013).
DITERPENES: CARNOSIC ACID, AND ROSMARINIC ACID
Carnosic and rosmarinic acids are two of the most important
antioxidant compounds in rosemary. They are parts of the bigger
family of phenolic acids and diterpenes, that have been extensively
Table 2 | Nutraceuticals in clinical trials: reference, dosage, and study quality (*low; **moderate; ***high; ****very high).
References Dosage Quality
Flavanols
Catechin, epicatechin,
epigallocatechin, EGCG
Krikorian et al. (2010a), Field et al. (2011),
Scholey et al. (2010)
6–9 ml/kg of grape juice, 720 mg of cocoa
ﬂavanols, 300 mg EGCG
*, **, **
Flavonols
Quercetin-kaempferol in
Gingko biloba
Birks and Grimley Evans (2009; Cochrane) 80–720 mg /day of EGb761 (Gb extract) ****
Isoflavones
Genistein, daidzein, glycetin
in soy
Kreijkamp-Kaspers et al. (2004), Thorp et al. (2009),
Henderson et al. (2012)
25.6 gr /day of soy protein, 116 mg/day
isoﬂavone equivalent, 25 mg/day of soy protein
***, **, ***
Anthocyanidins
Pelargonidin, cyanidine,
malvidin in berries
Krikorian et al. (2010b), Devore et al. (2012) 6–9 ml/kg of blueberry juice, dietary intake of
berries
*, ***
Resveratrol, curcumin Kennedy et al. (2010), Ringman et al. (2012) 250 or 500 mg resveratrol, Curcumin C3
Complex 2–4 gr/day
*, **
Carotenoids
Beta carotene, astaxanthin Grodstein et al. (2007), Zanotta et al. (2014) 50 mg/alternate days, extract of astaxanthin ***, **
Crocin Akhondzadeh et al. (2010) 30 mg/day saffron **
Vitamin B6, vitamin B12,
folic acid ±vit. B12, folic
acid, vit.B12, vit. B6
Malouf and Grimley Evans (2003) (Cochrane),
Malouf and Areosa Sastre (2009) (Cochrane), Malouf
and Grimley Evans (2008) (Cochrane), Ford and
Almeida (2012)
See reviewed studies **, **, ***, ***
For the Cochrane reviews the quality refers to the mean quality of the reported studies.
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studied (Yang et al., 2001; Kayashima and Matsubara, 2012). Both
carnosic and rosmarinic acid showed a neuroprotective action
both in in vitro models of neuronal death and in in vivo mod-
els of neurodegeneration. They scavenge reactive nitrogen species
(Qiao et al., 2005; Kelsey et al., 2010) and protect neuroblastoma
cells from hydrogen peroxide-induced oxidative stress (Lee et al.,
2008; Kelsey et al., 2010).
Diterpenes also signiﬁcantly alleviate memory impairment
associated with Aβ neurotoxicity in AD and signiﬁcantly delay
the onset of the disease (Kelsey et al., 2010; Shimojo et al., 2010).
Recently it has been found that carnosic acid has antiangiogenic
effects (Kayashima and Matsubara, 2012). The neuroprotective
effects of this substance, therefore,might be explained on the basis
of the recently identiﬁed role of angiogenesis in the formation of
β-amyloid plaques and the consequent neurotoxicity (Vagnucci
and Li, 2003). The exact mechanism by which carnosinic acid
inhibits angiogenesis is not clear; however, its antioxidant activity
seems to play an important antiangiogenic role.
CONCLUSION AND FUTURE PERSPECTIVE
When placed in the context of a healthy lifestyle behavior, age-
related changes in nutrition may play an important role in
brain functioning as well as in major organ functioning of old
people. Susceptibility of elderly population to speciﬁc nutrient
deﬁcits may exacerbate processes of cognitive decline. Indeed,
there is large evidence regarding beneﬁts of several nutrients
in the common diet towards cognitive impairment and other
diseases. There is great public and scientiﬁc interest about the
potential of nutritional supplementation to prevent age-related
diseases in general and cognitive decline in particular by counter-
acting deleterious neurodegenerative and pathological processes.
We reviewed several components of common diets and sev-
eral phytochemicals that have been shown to have beneﬁts on
these diseases and cognitive impairment. Unfortunately, there is
a substantial lack of well conducted studies to be included in
comparison analyses; scientiﬁc literature is still poor of RCTs
(a summary is reported in Table 2) for effects of some of
these molecules, and lots of studies are conducted on either
in vitro models or animal models. A very few studies testing
the effects of a combination of two substances or antioxidant
mixtures also display little beneﬁt against AD onset or progres-
sion as well as against the transition of MCI to AD. All critical
components of studies on nutraceuticals in cognitive impair-
ment, from sample size to cell types, to dosage to cognitive
measures used, are not comparable. For instance, diagnostic
criteria of MCI and AD as well as inclusion criteria and out-
comes are not homogeneous. Start and end of the intervention
with a particular nutraceutical in MCI or AD have been set for
logistic reasons mostly so that intervention begin occurs too
late during the course of the disease and study end delimits a
far too short intervention period. Finally, speciﬁc compound-
related issues might be responsible for the lack of clear success
of intervention, including dosage-, kinetic-, bioavailability-,
metabolic, and genetic-related issues that have been repeatedly
discussed (http://lpi.oregonstate.edu/infocenter/cognition.html;
Polidori and Schulz, 2014). Despite this, it seems difﬁcult to
uniform trial design and method in AD nutritional studies.
Theoretically, phytochemical-based treatments for geriatric
cognitive decline and depression could be moved into a stronger
clinical trial level on humans, especially due to their low toxi-
city and high bioavailability. Future studies addressing whether
short-term or long-term dietary intake of nutraceuticals can
reduce the severity and incidence of neurodegenerative and
other age-related diseases appear critical and important for the
future.
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